License To Market Leukemia Service in Canada

A dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2A is present in a high proportion of patients with myeloproliferative disorders (MPD) such as polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.

The president and CEO of Ipsogen, Vincent Fert, said, The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs.

Mark Busgang, president and CEO of Warnex commented, In addition to expanding our service offering in medical testing, this license provides Warnex with the exclusivity for JAK2 clinical testing performed in Canada, thus significantly enhancing our market position. Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders.


Related Links:
Warnex
Ipsogen SAS